Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Assess historical performance and potential in retirement for SP500 and Total Market funds, focusing on consistency and drawdown behavior.
28,444 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
January data show a pending home sales fall, signaling continued headwinds for buyers even as rates move modestly low...
As the Fed signals potential rate cuts, long-duration growth names with strong cash flows could re-rate. This piece f...
BitMine slashed its weekly Ethereum purchases by 74% to 26,659 ETH, just as it edges toward a 5% stake of circulating...
U.S. stocks push higher on May 27, 2026, as oil slips below $90 a barrel, lifting risk appetite. The S&P 500 and SPY ...
Eli Lilly is shaking up its growth plan by expanding beyond obesity with new infectious disease initiatives. This art...
Chip stocks rise on liquidity-driven rotations, but Morgan Stanley’s CIO cautions this may be near peak rather than a...
NVIDIA is forecast to surpass Apple in market capitalization by late July, even as Apple posts faster near-term growt...
OpenAI is nearing a private funding round that could push its valuation above $850 billion, a level that would outstr...
Oil breaks $100 again as Middle East tensions flare, lifting energy stocks and reshaping risk-on bets for 2026. Inves...
Stocks surged on a report of a potential Apple manufacturing pact with Intel, propelling INTC higher as markets weigh...
Despite rates rising to 6.75%, demand remains resilient and inventory growth stays modest. Early 2026 data point to h...